Source: Oncotarget From: news-medical.net A new editorial paper was published in Oncotarget’s Volume 14 on June 12, 2023, entitled, “Are cis-spliced fusion proteins pathological in more aggressive luminal breast cancer?” A vast majority of breast cancers (~70%) are estrogen receptor-alpha positive (ER+), for which endocrine therapy is the common treatment. However, recurrence often occurs leading to tumor progression, metastasis and …
Lipid-degrading enzyme, fatty acid amide hydrolase is a predictor of long-term survival in patients with breast cancer
By: By Dr. Sanchari Sinha Dutta, Ph.D. From: news-medical.net In a study published in the journal Nature Communications, scientists have identified a lipid-degrading enzyme, fatty acid amide hydrolase, as a prognostic biomarker in patients with luminal breast cancer. In both in vitro and in vivo experimental setups, this enzyme has been found to prevent cancer progression and lung metastasis. Background Breast …
Imaging features predict survival in patients with luminal breast cancer
By: Hannah Murphy From: healthimaging.com A new study published in Radiology highlights MRI findings that are indicative of survival outcomes in patients with luminal breast cancer. Women with luminal breast cancer achieve pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) infrequently (5-10%), and those with residual invasive disease are at an increased risk of relapse. For these reasons, the authors …